Their preliminary research showed that patients with progressive MS differed from controls in the blood methylation state of key myelin-related genes: MBP, myelin-associated glycoprotein (MAG), contactin 2 (CNTN2), brain-enriched myelin-associated protein 1 (BCAS1), partitioning defective 3 homolog (PARD3). This evidence concerns the gene CNTN2 and myeloid sarcoma.